15-min delayed · Sep 8, 1:30 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Insmed Inc, 20 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $169.00 to $245.00, a moderate spread. The average target of $208.32 sits 65% above the current $126.04. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.30 next quarter toward $0.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Strong Buy
Strong Buy00%
Buy20100%
Hold00%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Insmed Inc.
As of Sep, 20 of 20 firms rate INSM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
INSM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.30
Range $-1.12 – $0.35 · 16 analysts · -80% YoY
Next period, 16 analysts expect Insmed Inc to earn $-0.30 a share (range $-1.12 – $0.35), versus $-1.54 a year earlier. Full-year consensus is $-1.55, growing to $0.80 the year after.
REVENUE · NEXT QUARTER
$569.1M
Range $472.0M – $636.3M · 16 analysts · +116% YoY
Revenue is expected to reach $569.1M (range $472.0M – $636.3M), +115.7% year-over-year. Full-year consensus is $1.8B, rising to $2.9B next year.
Top analysts covering Insmed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INSM.
#1
Leonid Timashev
RBC Capital · Rank #33
Buy
$195.00+54.7% to target
Overall win rate
48%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$220.00+74.5% to target
Overall win rate
46%
+ Follow
#3
Jessica Fye
JP Morgan · Rank #71
Buy
$175.00+38.8% to target
Overall win rate
53%
+ Follow
#4
Matthew Harrison
Morgan Stanley · Rank #300
Buy
$212.00+68.2% to target
Overall win rate
45%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #345
Buy
$200.00+58.7% to target
Overall win rate
31%
+ Follow
INSM stock forecast FAQ
What is INSM's average 12-month price target?+
The 19 analysts with a live target average $208.32 for Insmed Inc over the next 12 months, ranging from a $245.00 high to a $169.00 low.
Is INSM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 20 analyst ratings, 20 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for INSM?+
The Street-high target is $245.00 (HC Wainwright & Co.), and the Street-low is $169.00 (Wells Fargo). The average of all 19 active targets is $208.32.
How many Wall Street analysts cover INSM?+
20 analysts have an active rating on Insmed Inc, and 19 firms carry a live 12-month price target.
Who is the most accurate analyst covering INSM?+
Among analysts who currently cover INSM, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #33). Their current call is Buy with a $195.00 target.
What is Insmed Inc's projected EPS for next quarter?+
The consensus estimate is $-0.30 per share (range $-1.12 – $0.35) across 16 analysts. Full-year EPS is projected at $-1.55, rising to $0.80 the following year.
How much revenue is Insmed Inc expected to report next quarter?+
Consensus revenue is $569.1M (range $472.0M – $636.3M). Full-year revenue is projected at $1.8B, growing to $2.9B next year.
Have analysts been upgrading or downgrading INSM lately?+
As of Sep, 20 of 20 firms rate INSM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INSM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
